Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy | Zendy

Samuel J. Klempner | Zendy; Munveer S. Bhangoo | Zendy; Hubert Y. Luu | Zendy; Seung Tae Kim | Zendy; Joseph Chao | Zendy; KyoungMee Kim | Zendy; Jeeyun Lee | Zendy

Open Access

Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy

Author(s) -

Samuel J. Klempner,

Munveer S. Bhangoo,

Hubert Y. Luu,

Seung Tae Kim,

Joseph Chao,

KyoungMee Kim,

Jeeyun Lee

Publication year - 2018

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.084

H-Index - 39

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2018.09.04

Subject(s) - medicine , oncology , cohort , cancer , proportional hazards model , hazard ratio , chemotherapy , pathology , confidence interval

Gastric cancer (GC) is a leading cause of cancer-specific mortality with limited biologically informed treatments. The ataxia telangiectasia mutated ( ATM ) gene is critically involved in the repair of double-stranded DNA breaks and a component of DNA damage repair (DDR) pathways. Platinum salts are hypothesized to have increased efficacy in tumors deficient in DDR pathways. We sought to investigate an association between ATM status and response to XELOX in a homogenous first line GC patient cohort.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research